Management of United Airway Disease Focused on Patients With Asthma and Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review
Authors:
- 12 May 2022
- journal article
- review article
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 10 (9) , 2438-2447.e9
Abstract
No abstract availableKeywords
Funding Information
- Sanofi España
- Sanofi Genzyme
This publication has 44 references indexed in Scilit:
- Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational studyPulmonary Pharmacology & Therapeutics, 2019
- Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal PolypsThe Journal of Allergy and Clinical Immunology: In Practice, 2019
- Diagnosis and management of NSAID‐Exacerbated Respiratory Disease (N‐ERD)—a EAACI position paperAllergy, 2018
- Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe AsthmaNew England Journal of Medicine, 2018
- Precision medicine in united airways disease: A “treatable traits” approachAllergy, 2018
- A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory diseaseThe Journal of Allergy and Clinical Immunology: In Practice, 2018
- Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trialJournal of Allergy and Clinical Immunology, 2017
- Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe AsthmaNew England Journal of Medicine, 2017
- Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal PolyposisJAMA, 2016
- Association between Severity of Asthma and Degree of Chronic RhinosinusitisAmerican Journal of Rhinology & Allergy, 2011